National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Nivolumab (Opdivo®) for the treatment of squamous cell carcinoma of the head and neck (SCCHN) in adults progressing on or after platinum-based therapy.

 

Rapid Review

Commenced Completed Outcome
03/05/2017 30/05/2017 Full Pharmacoeconomic Evaluation Recommended at the Submitted Price

 

The HSE has approved reimbursement following confidential price negotiations: May 2018